ITM Isotope Technologies Munich SE and Telix Pharmaceuticals, two prominent players in the fast‑growing radiopharmaceutical sector, are joining forces in a transaction valued at no less than $1.65 billion.
Under the agreement, Telix will acquire all outstanding shares of the privately held ITM. Additionally, Telix may owe up to another $700 million to ITM’s shareholders if the company’s lead drug achieves specified regulatory and sales milestones.
The combined entity adds a well‑financed competitor to the radiopharmaceutical landscape, a field currently led by Novartis. These therapies deliver radioactive isotopes directly to malignant cells. Novartis energized the arena with the introduction of its two such agents in 2018 and 2022.
Also Read
- It’s Hard To Predict Who Will Be Suicidal. It’s Easier To Ensure People Can’t Shoot Themselves.
- Patrick Clancy’s 60 Minutes Interview Shows Why Partners Need Postpartum Mental Health Guidance Before a Crisis Begins
- ‘Our culture is rich and we need our own space’: the fight to build a permanent centre for Deaf people
- Equitable vaccine distribution could spare nearly three million lives in future pandemics, study finds
